inclisiran
Sign in to saveAlso known as Leqvio, ALN-PCS
Inclisiran, sold under the brand name Leqvio, is a medication used for the treatment of high low-density lipoprotein (LDL) cholesterol and for the treatment of people with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk-equivalents, and heterozygous familial hypercholesterolemia (HeFH). It is a small interfering RNA (siRNA) that acts as an inhibitor of a proprotein convertase, specifically, inhibiting translation of the protein PCSK9.
Key facts
- Drug.image
- Inclisiran.svg
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Leqvio
- Drug.MedlinePlus
- a622009
- Drug.DailyMedID
- Inclisiran
- Drug.pregnancy_AU
- B1
- Drug.routes_of_administration
- Subcutaneous
- Drug.class
- Antilipemic agent
- Drug.ATC_prefix
- C10
- Drug.ATC_suffix
- AX16
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.legal_status
- Rx-only
- Drug.CAS_number
- 1639324-58-5
- Drug.DrugBank
- DB14901
- Drug.UNII
- UOW2C71PG5
via Wikipedia infobox
Research
694 papers- Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.The New England journal of medicine · 2020
- Inclisiran: First Approval.Drugs · 2021
- Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial.Cardiovascular research · 2024
- Inclisiran: A Review in Hypercholesterolemia.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2023
- Inclisiran: a new generation of lipid-lowering siRNA therapeutic.Frontiers in pharmacology · 2023
via PubMed
~7 min read
Encyclopedic overview
8 sectionsContents
- Medical uses
- Mechanism of action
- History
- Society and culture
- Economics
- References
- Further reading
- External links
Inclisiran, sold under the brand name Leqvio, is a medication used for the treatment of high low-density lipoprotein (LDL) cholesterol and for the treatment of people with atherosclerotic cardiovascular disease (ASCVD), ASCVD risk-equivalents, and heterozygous familial hypercholesterolemia (HeFH). It is a small interfering RNA (siRNA) that acts as an inhibitor of a proprotein convertase, specifically, inhibiting translation of the protein PCSK9.
Inclisiran was approved for use in the European Union in December 2020. In August 2021, it received NICE approval for use by the National Health Service in the UK. In December 2021, it was approved for medical use in the United States. The U.S. Food and Drug Administration considers it to be a first-in-class medication. In August 2023, the National Medical Products Administration approved the use of inclisiran in China.
Excerpted from Wikipedia’s “inclisiran” article, available under the CC BY-SA 4.0 licence.